Literature DB >> 7002183

Non-migrainous headache for the evaluation of oral analgesics.

B von Graffenried, E Nüesch.   

Abstract

1 Eight double-blind, randomized, placebo-controlled, single-dose, cross-over studies were carried out to evaluate the usefulness of testing the acute analgesic effect of drugs in out-patients with non-migrainous headache. 2 The reference compounds were either (1) aspirin, (2) a combination of aminopyrine, caffeine and butalbarbital (Optalidon), and (3) a combination of (2) with dihydroergotamine (Tonopan). 3 The test compounds were (1) proquazone, (2) fluproquazone and (3) and (4), new formulations of Optalidon and Tonopan in which the aminopyrine was replaced by propyphenazone. They were all found to be active. 4 A significant, dose-response relationship was established for aspirin (250, 500 and 1000 mg). 5 It is concluded that the non-migrainous headache model is a practical, reproducible and sensitive method for the investigation of the acute efficacy of analgesics.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002183      PMCID: PMC1430191          DOI: 10.1111/j.1365-2125.1980.tb01804.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  TREATMENT OF CHRONIC TENSION HEADACHE.

Authors:  J W LANCE; D A CURRAN
Journal:  Lancet       Date:  1964-06-06       Impact factor: 79.321

2.  The use of postpartum patients in evaluating analgesic drugs. The effectiveness of dextropropoxyphene, codeine, and meperidine when administered orally with acetylsalicylic acid compound and alone.

Authors:  C M GRUBER; J DOSS; A BAPTISTI; S M CHERNISH
Journal:  Clin Pharmacol Ther       Date:  1961 Jul-Aug       Impact factor: 6.875

3.  Comparative efficacy of ibuprofen and aspirin in episiotomy pain.

Authors:  S S Bloomfield; T P Barden; J Mitchell
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

4.  A comparative analgesia study of propoxyphene hydrochloride, propoxyphene napsylate, and placebo.

Authors:  A Sunshine; E Laska; J Slafta; E Fleischman
Journal:  Toxicol Appl Pharmacol       Date:  1971-07       Impact factor: 4.219

Review 5.  Mild analgesics. A review of their clinical pharmacology. II.

Authors:  W T Beaver
Journal:  Am J Med Sci       Date:  1966-05       Impact factor: 2.378

Review 6.  Mild analgesics. A review of their clinical pharmacology.

Authors:  W T Beaver
Journal:  Am J Med Sci       Date:  1965-11       Impact factor: 2.378

7.  Primary dysmenorrhea: alleviation by an inhibitor of prostaglandin synthesis and action.

Authors:  A Schwartz; U Zor; H R Lindner; S Naor
Journal:  Obstet Gynecol       Date:  1974-11       Impact factor: 7.661

8.  Chronic tension headache--treated with amitriptyline--a double-blind study.

Authors:  S Diamond; B J Baltes
Journal:  Headache       Date:  1971-10       Impact factor: 5.887

  8 in total
  6 in total

Review 1.  Aspirin for acute treatment of episodic tension-type headache in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

2.  The clinical assessment of analgesic drugs.

Authors:  D W Littlejohns; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 3.  Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states.

Authors:  S P Clissold; R Beresford
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

Review 4.  Current and potential future drug therapies for tension-type headache.

Authors:  Sait Ashina; Messoud Ashina
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 5.  Should butalbital-containing analgesics be banned? Yes.

Authors:  William B Young; Hua Chiang Siow
Journal:  Curr Pain Headache Rep       Date:  2002-04

Review 6.  Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.

Authors:  Denis M McCarthy
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-04       Impact factor: 3.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.